网站 微信 微博

中文核心期刊
中国科技核心期刊
RCCSE 中国核心学术期刊
中国科学引文数据核心库来源期刊

QK2107853

ISSN 1000-484X
CN 22-1126/R

Chinese Journal of Immunology

中国免疫学杂志®

ZHONG GUO MIAN YI XUE ZA ZHI



ISSN 1000-484X

9 771000 484213 06>

中国免疫学会会刊

万方数据

2021 6

March 2021

第37卷 第6期

Volume37 Number6

中国免疫学杂志

Zhongguo Mianyixue Zazhi

半月刊　1985年1月创刊　第37卷　第6期　2021年3月27日出版

主　管
中国科学技术协会
主　办
中国免疫学会
100005，北京市东单三条5号
吉林省医学期刊社
130061，长春市建政路971号
编　辑
中国免疫学杂志编辑委员会
130061，长春市建政路971号
电话（传真）：(0431)88925027
E-mail：zhmizazh@126.com
网址：www.immune99.com
www.中国免疫学.中国
主　编　田志刚
编辑部主任　张晓舟
责任编辑　周文瑜　张晓舟
出　版
中国免疫学杂志编辑部
130061，长春市建政路971号
电话：(0431)88925027
广告经营许可证
2200041001010
印　刷
吉林方鼎印业有限公司
发　行
国内：长春市报刊发行局
国外：中国国际图书贸易总公司
（北京399信箱，100044）
代号SM6689
订　阅
全国各地邮局
邮发代号12-89
邮　购
中国免疫学杂志编辑部
130061，长春市建政路971号
电话（传真）：(0431)88925027
E-mail：zhmizazh@126.com
定　价（国内）
单价18.00元，全年432.00元
中国标准连续出版物号
ISSN 1000-484X
CN 22-1126/R
如有印装质量问题，请向编辑部调换

目次

基础免疫学

中医中药与免疫

期刊基本参数：CN22-1126/R＊1985＊sm＊A4＊128＊zh＊P＊18.00＊1500＊23＊2021-6＊n

本期审稿人名单

(按姓氏拼音字母顺序排列)

鲍时华 柏银兰 常晓彤 陈益国 储以微 官 妍 郭 林 李 霞
李 一 刘星光 吕仕超 孟繁平 单凤平 王红艳 吴晓牧 徐 涛
闫东梅 叶韵斌 张丁丁 张纪岩 张 建 郑利民 卓孝福 左大明

Chinese Journal of Immunology

Semimonthly Established in January 1985 Volume 37 Number 6, March 27, 2021

Responsible institution
China Association for Science and Technology
Sponsor
Chinese Society of Immunology
5, Dongdan Santiao, Beijing 100005 China
Medical Periodical Society of Jilin
971, Jianzheng Road, Changchun 130061, China
Editing
Editorial Board of Chinese Journal of Immunology
971, Jianzheng Road, Changchun 130061, China
Tel(Fex): (86-431)88925027
E-mail: zhmizhzh@126.com
Web. site: www.inmune99.com
www. 中国免疫学. 中国
Editor-in-Chief
TIAN Zhi-Gang(田志刚)
Managing Director
ZHANG Xiao-Zhou(张晓舟)
Executive Editor
ZHOU Wen-Yu(周文瑜)
ZHANG Xiao-Zhou(张晓舟)
Publishing
Editorial Board of Chinese Joural of Immunology
971, Jianzheng Road, Changchun 130061, China
Tel: (86-431)88925027
Advertisement Management Licence
2200041001010
Printing
Jilin Fangding Printing Limited Corporation
Distributor
Domestic Distributor:
Newspapers and Periodicals Issue Office of Changchun
Overseas Distributor:
China International Book Trading Corporation
(P. O. Box399, Beijing, P. R. China)
Code No. SM6689
Subscribing
Local Post Office in China
Issue Code 12-89
Mail-Order
Editorial Board of Chinese Journal of Immunology
971, Jianzheng Road, Changchun 130061, China
Tel: (86-431) 88925027
E-mail: zhmizhzh@126.com
CSSN
ISSN 1000-484X
CN 22-1126/R

CONTENTS IN BRIEF

11-1620.

[42] LI G, WANG Z, ZHANG C, *et al*. Molecular and clinical. characterization of TIM-3 in glioma through 1,024 samples [J]. Oncolmmunol, 2017, 6(8): e1328339. DOI: 10.1080/2162402X.2017.1328339.

[43] KURZ S C, CABRERA L P, HASTIE D, *et al*. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma [J]. Neurology, 2018, 91(14): e1355-e1359. DOI: 10.1212/WNL.0000000000006283.

[44] CASTRO M G, BAKER G J, LOWENSTEIN P R. Blocking immunosuppressive checkpoints for glioma therapy: The more the Merrier! [J]. Clin Cancer Res, 2014, 20(20): 5147-5149. DOI: 10.1158/1078-0432.CCR-14-0820.

[45] FOURCADE J, SUN Z, BENALLAOUA M, *et al*. Upregulation of tim-3 and PD-1 expression is associated with tumor antigen-specific CD8$^+$T cell dysfunction in melanoma patients [J]. J Exp Med, 2010, 207(10): 2175-2186. DOI: 10.1084/jem.20100637.

[46] HARRIS-BOOKMAN S, MATHIOS D, MARTIN A M, *et al*. Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma [J]. Int J Cancer, 2018, 143(12): 3201-3208. DOI: 10.1002/ijc.31661.

[47] FRANCISCO L M, SALINAS V H, BROWN K E, *et al*. PD-L1. regulates the development, maintenance, and function of induced regulatory T cells [J]. J Exp Med, 2009, 206(13): 3015-3029. DOI: 10.1084/jem.20090847.

[48] MBONGUE J C, NICHOLAS D A, TORREZ T W, *et al*. The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity [J]. Vaccines, 2015, 3(3): 703-729. DOI: 10.3390/vaccines3030703.

[49] MUNN D H, SHARMA M D, MELLOR A L. Ligation of B7-1/ B7-2 by human CD4$^+$T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells [J]. J Immunol, 2004, 172(7): 4100-4110. DOI: 10.4049/jimmunol.172.7.4100.

[50] KLINE C, LIU S J, DURISETI S, *et al*. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: A single-institution experience [J]. J Neurooncol, 2018, 140(3): 629-638. DOI: 10.1007/s11060-018-2991-5.

[51] SHARABI A B, LIM M, DEWEESE T L, *et al*. Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy [J]. Lancet Oncol, 2015, 16(13): e498-e509. DOI: 10.1016/S1470-2045(15)00007-8.

[52] DAI B, QI N, LI J, *et al*. Temozolomide combined with PD-1 antibody therapy for mouse orthotopic glioma model [J]. Biochem Biophys Res Commun, 2018, 501(4): 871-876. DOI: 10.1016/j.bbrc.2018.05.064.

[53] HANIHARA M, KAWATAKI T, OH-OKA K, *et al*. Synergistic. antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model [J]. J Neurosurg, 2016, 124(6): 1594-1601. DOI: 10.3171/2015.5.JNS141901.

[54] YI M, JIAO D, QIN S, *et al*. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment [J]. Mol Cancer, 2019, 18(1): 60. DOI: 10.1186/s12943-019-0974-6.

[55] VORON T, COLUSSI O, MARCHETEAU E, *et al*. VEGF-A modulates expression of inhibitory checkpoints on CD8$^+$T cells in tumors [J]. J Exp Med, 2015, 212(2): 139-148. DOI: 10.1084/jem.20140559.

[56] TAMURA R, TANAKA T, OHARA K, *et al*. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab [J]. Cancer Sci, 2019, 110(2): 499-508. DOI: 10.1111/cas.13889.

[57] 姜运峰,董晓鹏,赵小刚. PD-1单克隆抗体联合血管内皮抑素在Lewis肺癌小鼠的抗肿瘤效应 [J]. 山东大学学报, 2018,56(9): 11-16. DOI: 10.6040/j.issn.1671-7554.0.2018.251.

[58] WEI J, NDUOM E K, KONG L Y, *et al*. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints [J]. Neuro Oncol, 2016, 18(5): 639-648. DOI: 10.1093/neuonc/nov292.

[59] WANG Y, WANG L. miR-34a attenuates glioma cells progression and chemoresistance via targeting PD-L1 [J]. Biotechnol Lett, 2017, 39(10): 1485-1492. DOI: 10.1007/s10529-017-2397-z.

[60] PARSA A T, WALDRON J S, PANNER A, *et al*. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma [J]. Nat Med, 2007, 13(1): 84-88. DOI: 10.1038/nm1517.

[61] DORAND R D, NTHALE J, MYERS J T, *et al*. Cdk5 disruption attenuates tumor PDL1 expression and promotes antitumor immunity [J]. Science, 2016, 353(6297): 399-403. DOI: 10.1126/science.aae0477.

[62] JAHAN N, TALAT H, ALONSO A, *et al*. Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody.is highly effective against murine intracranial glioma [J]. Oncoimmunology, 2019, 8(5): e1577108. DOI: 10.1080/2162402X.2019.1577108.

[63] ZHU S, LV X, ZHANG X, *et al*. An effective dendritic cell-based vaccine containing glioma stem-like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma [J]. Int J Cancer, 2019, 144(11): 2867-2879. DOI: 10.1002/ijc.32008.

[64] SAHA D, MARTUZA R L, RABKIN S D. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma [J]. Immunotherapy, 2018, 10(9): 779-786. DOI: 10.2217/imt-2018-0009.

[65] WU A, MAXWELL R, XIA Y, *et al*. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment [J]. J Neurooncol, 2019, 143(2): 241-249. DOI: 10.1007/s11060-019-03172-5.

[收稿 2019-08-22 修回 2019-09-18]
(编辑 陈 阳)

邮发代号 12-89 半年价 216.00元 单价 18.00元